The estimated Net Worth of R Scott Greer is at least $746 Tisíc dollars as of 9 November 2021. Mr. Greer owns over 12,500 units of Nektar Therapeutics stock worth over $366,718 and over the last 21 years he sold NKTR stock worth over $0. In addition, he makes $379,228 as Independent Director at Nektar Therapeutics.
Sign up
Mr. Greer NKTR stock SEC Form 4 insiders trading
R has made over 15 trades of the Nektar Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of NKTR stock worth $160,000 on 9 November 2021.
The largest trade he's ever made was exercising 45,000 units of Nektar Therapeutics stock on 31 August 2021 worth over $571,500. On average, R trades about 6,059 units every 42 days since 2003. As of 9 November 2021 he still owns at least 293,374 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Greer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
R. Scott Greer biography
R. Scott Greer is Independent Director of the Company. Mr. Greer currently serves as Managing Director of Numenor Ventures, LLC, a venture capital firm. In 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He also served as a director of Abgenix from 1996 and Chairman of the board of directors from 2000 until the acquisition of Abgenix by Amgen, Inc. in April 2006. Prior to Abgenix’s formation, Mr. Greer held senior management positions at Cell Genesys, Inc., a biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development, and various positions at Genetics Institute, Inc., a biotechnology research and development company. He currently serves as a member of the board of directors of Inogen, Inc., a medical device company that develops and markets oxygen therapy products. Mr. Greer served as a member of the board of directors of Sientra, Inc., a medical aesthetics company from 2014-2018, Versartis, Inc., an endocrine focused biopharmaceutical company from 2014-2018, Auspex Pharmaceuticals, a biopharmaceutical company developing drugs for patients with movement disorders and other rare diseases from 2014-2015, Sirna Therapeutics, Inc., a biotechnology company, from 2003, and as its Chairman of the board of directors from 2005, through the closing of the acquisition of Sirna by Merck & Co., Inc. in December 2006. From 2001 to 2005, Mr. Greer served as a member of the board of directors of Illumina, Inc., a provider of integrated systems for the analysis of genetic variation and biological function; and from 2001 to 2004, he served as member of the board of directors of CV Therapeutics, Inc., a biotechnology company.
What is the salary of R Greer?
As the Independent Director of Nektar Therapeutics, the total compensation of R Greer at Nektar Therapeutics is $379,228. There are 13 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
How old is R Greer?
R Greer is 61, he's been the Independent Director of Nektar Therapeutics since 2010. There are 7 older and 11 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
What's R Greer's mailing address?
R's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Insiders trading at Nektar Therapeutics
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie a John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
What does Nektar Therapeutics do?
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
What does Nektar Therapeutics's logo look like?
Complete history of Mr. Greer stock trades at Illumina Inc, Inogen Inc, Nektar Therapeutics a Sientra Inc
Nektar Therapeutics executives and stock owners
Nektar Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Zalevsky,
Chief Research and Development Officer -
Howard Robin,
President, Chief Executive Officer, Director -
Gilbert Labrucherie,
Chief Financial Officer, Chief Operating Officer, Senior Vice President -
John Northcott,
Senior Vice President and Chief Commercial Officer -
Howard W. Robin,
CEO, Pres & Director -
Jillian Thomsen,
Senior Vice President - Finance, Chief Accounting Officer -
Gilbert M. Labrucherie J.D.,
Sr. VP, CFO & COO -
Dr. Jonathan Zalevsky,
Chief R&D Officer -
John P. Northcott,
Sr. VP & Chief Commercial Officer -
Mark A. Wilson,
Sr. VP, Gen. Counsel & Sec. -
Myriam Curet,
Independent Director -
Robert Chess,
Independent Chairman of the Board -
Roy Whitfield,
Lead Independent Director -
R. Scott Greer,
Independent Director -
Karin Eastham,
Independent Director -
Jeff Ajer,
Independent Director -
Dr. Brian L. Kotzin,
Sr. VP of Clinical Devel. & Head of Immunology -
Dr. Mary Tagliaferri L.Ac., M.D.,
Sr. VP & Exec. Clinical Fellow -
Jennifer Ruddock,
Sr. VP of Strategy & Corp. Affairs -
Robert Bacci,
Sr. VP of HR and Facilities -
Jillian B. Thomsen,
Sr. VP of Fin. & Chief Accounting Officer -
Lutz Lingnau,
Director -
Dennis L Winger,
Director -
Ivan P. Gergel,
SVP Drug Development & CMO -
Maninder Hora,
SVP Pharma Dev and Mfg -
Christopher A Kuebler,
Director -
Joseph J Krivulka,
Director -
Melvin Perelman,
Director -
Ajit Gill,
CEO & President -
Track Capital, Lp Deep Trac...,
-
Randall W Moreadith,
SVP Drug Development -
Bharat M Chowrira,
COO & Head of PEGylation BU -
Robert Medve,
Chief Medical Officer -
Nevan C Elam,
General Counsel and Secretary -
Timothy Harkness,
SVP & Chief Financial Officer -
John Stuart Patton,
Chief Scientific Officer -
Irwin Lerner,
Director -
Michael A/Ca Brown,
Director -
Masuoka K. Lorianne,
SVP & Chief Medical Officer -
Susan Wang,
Director -
Rinko Ghosh,
SVP & Chief Business Officer -
David Johnston,
SVP, Research & Development -
Ajay Bansal,
CFO, VP Finance & Admin -
Hoyoung Huh,
Chief Operating Officer -
J Milton Harris,
President of Nektar AL -
James B Glavin,
Director -
John Nicholson,
SVP & Chief Operating Officer -
Stephen K Doberstein,
SVP & Chief Scientific Officer -
Gil M Labrucherie,
SVP, COO & CFO -
Diana Brainard,
Director -
Mark Andrew Wilson,
Chief Legal Officer